【TMCLIFE 0101 交流专区】TMC生命科学

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 29 Feb 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		Three Months	Three Months	Six Months	Six Months
		01 Dec 2019 To	01 Dec 2018 To	01 Sep 2019 To	01 Sep 2018 To
		29 Feb 2020	28 Feb 2019	29 Feb 2020	28 Feb 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	50,894	0	103,428	0
2	Profit/(loss) before tax	8,632	0	19,297	0
3	Profit/(loss) for the period	6,823	0	14,776	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,823	0	14,776	0
5	Basic earnings/(loss) per share (Subunit)	0.39	0.00	0.85	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4500		0.4400

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 May 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		Three Months	Three Months	Nine Months	Nine Months
		01 Mar 2020 To	01 Mar 2019 To	01 Sep 2019 To	01 Sep 2018 To
		31 May 2020	31 May 2019	31 May 2020	31 May 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	34,873	0	138,301	0
2	Profit/(loss) before tax	-4,555	0	14,742	0
3	Profit/(loss) for the period	-4,301	0	10,475	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	-4,301	0	10,475	0
5	Basic earnings/(loss) per share (Subunit)	-0.25	0.00	0.60	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4400		0.4400

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		One Month	One Month	Ten Months	Ten Months
		01 Jun 2020 To	01 Jun 2019 To	01 Sep 2019 To	01 Sep 2018 To
		30 Jun 2020	30 Jun 2019	30 Jun 2020	30 Jun 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	15,105	0	153,406	0
2	Profit/(loss) before tax	3,678	0	18,420	0
3	Profit/(loss) for the period	2,800	0	13,275	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,800	0	13,275	0
5	Basic earnings/(loss) per share (Subunit)	0.16	0.00	0.76	0.00
6	Proposed/Declared dividend per share (Subunit)	0.17	0.00	0.17	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4400		0.4400

TMC LIFE SCIENCES BERHAD

Entitlement subject	Final Dividend
Entitlement description	Single-Tier Final Dividend of 0.1678 sen per Ordinary Share
Ex-Date	04 Dec 2020
Entitlement date	07 Dec 2020
Entitlement time	5:00 PM
Financial Year End	30 Jun 2020
Period
Share transfer book & register of members will be	to  closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	04 Jan 2021
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	07 Dec 2020
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0017

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2020	30 Sep 2019	30 Sep 2020	30 Sep 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	50,827	0	50,827	0
2	Profit/(loss) before tax	10,621	0	10,621	0
3	Profit/(loss) for the period	7,784	0	7,784	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	7,784	0	7,784	0
5	Basic earnings/(loss) per share (Subunit)	0.45	0.00	0.45	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4500		0.4400

TMC LIFE SCIENCES BERHAD

Date of change	31 Dec 2020
Name	PROFESSOR EMERITUS DATO' DR. KHALID BIN ABDUL KADIR
Age	72
Gender	Male
Nationality	Malaysia
Designation	Chairman
Directorate	Non Independent and Non Executive
Type of change	Resignation
Reason	medical reason and personal interest
Details of any disagreement that he/she has with the Board of Directors	No
Whether there are any matters that need to be brought to the attention of shareholders	No

Qualifications

No

Qualifications

Major/Field of Study

Institute/University

Additional Information

Working experience and occupation	N/A
Family relationship with any director and/or major shareholder of the listed issuer	NIL
Any conflict of interests that he/she has with the listed issuer	NIL
Details of any interest in the securities of the listed issuer or its subsidiaries	TMC Life Sciences Berhad:- Direct interest: 500,000 Ordinary Shares (0.03%)- Indirect interest: 200,000 Ordinary Shares (0.01%)

Date of change	01 Jan 2021
Name	DATO' SRI MOHD MOKHTAR BIN MOHD SHARIFF
Age	63
Gender	Male
Nationality	Malaysia
Type of change	Redesignation
Previous Position	Director
New Position	Chairman
Directorate	Independent and Non Executive

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Masters	Masters of Business Administration	Phoenix International University
2	Professional Qualification	Certificate of Legal Practice	Legal Profession Qualifying Board of Malaysia
3	Degree	Bachelor of Law (Hons)	University of Wolverhampton

Working experience and occupation

1.        Admitted as Advocate & Solicitors of High Court of Malaya on 13 September 2019.2.        Director of Special Branch from September 2017 to May 2018. 3.        Director Narcotics and Crime Investigation Department from April 2015 to September 2017. 4.        Chief Police Officer of State of Johor from January 2008 to April 2015. 5.        Deputy Chief Police Officer of State of Johor from March 2007 to January 2008. 6.        Deputy Chief Police Officer of State of Pahang from April 2006 to March 2007. 7.        Head of Special Branch, Kuala Lumpur from December 2004 to April 2006. 8.        Police Attaché, Embassy of Malaysia, Bangkok from December 2002 to February 2004. 9.        Staff Officer of Special Branch, Bukit Aman Headquarters from 1996 to 2002. 10.        Assistant Police Attaché, Embassy of Malaysia, Bangkok from June 1987 to June 1996. 11.        Staff Officer of Special Branch, Police Headquarters from April 1978 to June 1987.

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2020	31 Dec 2019	31 Dec 2020	31 Dec 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	48,794	0	99,621	0
2	Profit/(loss) before tax	6,979	0	17,600	0
3	Profit/(loss) for the period	5,401	0	13,185	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	5,401	0	13,185	0
5	Basic earnings/(loss) per share (Subunit)	0.31	0.00	0.76	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4500		0.4400

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2021

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2021	30 Sep 2020	30 Sep 2021	30 Sep 2020
		$$'000	$$'000	$$'000	$$'000

1	Revenue	52,681	50,827	52,681	50,827
2	Profit/(loss) before tax	5,323	10,621	5,323	10,621
3	Profit/(loss) for the period	4,046	7,784	4,046	7,784
4	Profit/(loss) attributable to ordinary equity holders of the parent	4,046	7,784	4,046	7,784
5	Basic earnings/(loss) per share (Subunit)	0.23	0.45	0.23	0.45
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4600		0.4500

icy97

TMC LIFE SCIENCES BERHAD

Date of change	29 Jan 2024
Name	DR HENG JUN LI MELVIN
Age	41
Gender	Male
Nationality	Singapore
Type of change	Redesignation
Previous Position	Non Executive Director
New Position	Group Chief Executive Officer
Directorate	Executive

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Masters	Masters of Business Administration	Frankfurt School of Finance & Management
2	Degree	Bachelor of Medicine and Bachelor of Surgery ("MBBS")	University of London, St Georges Hospital
3	Diploma	Graduate Diploma Occupational Medicine	National University of Singapore

Working experience and occupation	Thomson Medical Group Limited, Singapore1 December 2022 to presentExecutive Director and Group Chief Executive OfficerGleneagles Hospital, IHH Healthcare January 2021 to 31 October 2022 Chief Executive OfficerJuly 2019 to December 2020 Chief Operating OfficerSeptember 2017 to June 2019 AVP, Operations Mesh Bio Pte Ltd July 2018 to Present Co-Founder & Medical AdvisorMinistry of Health, Singapore August 2016 to January 2018 Medical AdvisorGlobal Health Byte Holdings Pte Ltd (UNO Technologies Pte Ltd) June 2016 to December 2018 Investor & Medical AdvisorOneCare Medical Pte Ltd August 2014 to September 2017 Equity PartnerGlobal Medical Concierge Pte Ltd January 2013 to June 2017 Co-FounderTan Tock Seng Hospital January 2013 to March 2015 Medical Doctor, RadiologyNational Health Service (United Kingdom) June 2009 to August 2011 Medical Doctor
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Nil

Remarks :

Dr Heng Jun Li Melvin will assume the role of Acting Group Chief Executive Officer of the Company on 29 January 2024.

ype	Announcement
Subject	OTHERS
Description	TMC Life Sciences Berhad ("the Company") - Suspension of Group Chief Executive Officer
On behalf of the Company, the Board of Directors ("the Board") wishes to announce that the Company has suspended the employment of Puan Wan Nadiah Binti Wan Mohd Abdullah Yaakob as the Group Chief Executive Officer (“GCEO”) of the Company and the Chief Executive Officer (“CEO”) of Thomson Hospitals Sdn. Bhd., resulting in the powers, authorities and functions vested in her as the GCEO and CEO to be suspended with effect from 29 January 2024 until further announcement by the Board. The Board wishes to announce further that the Company will continue its business as usual and during the period of suspension, one of our Directors, Dr. Heng Jun Li Melvin, will be appointed as the Acting GCEO, who will temporarily assume the duties and functions of GCEO. The Company shall announce further developments on the above matter as and when necessary. This announcement is dated 29 January 2024.

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-30012024-00001
Subject	SUSPENSION OF GROUP CHIEF EXECUTIVE OFFICER
Description	TMC Life Sciences Berhad ("the Company") - Suspension of Group Chief Executive Officer
Query Letter Contents	We refer to your Company’s announcement dated 29 January 2024, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1)     To clarify the circumstances/reasons leading to the suspension of Puan Wan Nadiah Binti Wan Mohd Abdullah Yaakob as the Group Chief Executive Officer. 2)     To briefly clarify the next course of action to be taken by the Company arising from the suspension and to indicate the estimated timeline to resolve the matter.
With reference to the announcement made on 29 January 2024 and the query raised by Bursa Malaysia Securities Berhad by way of its letter of 30 January 2024, on behalf of the Company, the Board of Directors (“the Board”) wishes to clarify that the suspension of Puan Wan Nadiah Binti Wan Mohd Abdullah Yaakob (“Puan Wan Nadiah”) is to facilitate internal disciplinary process relating to allegations stated in a show cause letter issued to her on 29 January 2024. Puan Wan Nadiah has been given 7 days (up to 5 February 2024) to submit her written reply to the said show cause letter. If she requires more time, Puan Wan Nadiah may be granted an additional 7 days to submit her written reply. If submitted within the time permitted, her written reply to the show cause letter will then be considered and deliberated to determine whether the next course of action in the disciplinary process is necessary. Mindful of the proceedings applicable by law and considering that several factors usually determine and dictate the exact time frame involved, the Board is unable, at this juncture, to estimate the timeframe involved to resolve this matter. The Board took the view that in light of the on-going disciplinary process, the outcome of which can only be determined at a later date as well as the confidentiality surrounding the allegations, immediate disclosure of the facts or circumstances regarding the suspension would prejudice the outcome of the disciplinary process. Furthermore, the facts of the matter are still in a state of flux and a more appropriate moment for disclosure is imminent. The Board wishes to assure Bursa Malaysia Securities Berhad that future announcement(s) will be made at the appropriate moment. The Board wishes to give further assurance that every step is taken to maintain this matter at its strictest confidentiality. This announcement is dated 31 January 2024.

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2023

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2023	31 Dec 2022	31 Dec 2023	31 Dec 2022
		$$'000	$$'000	$$'000	$$'000

1	Revenue	93,783	73,341	186,221	145,212
2	Profit/(loss) before tax	19,680	7,682	39,823	16,410
3	Profit/(loss) for the period	14,524	5,490	29,664	11,718
4	Profit/(loss) attributable to ordinary equity holders of the parent	14,524	5,490	29,664	11,718
5	Basic earnings/(loss) per share (Subunit)	0.83	0.32	1.70	0.67
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.5000		0.4900

Type	Announcement
Subject	OTHERS
Description	TMC LIFE SCIENCES BERHAD ("TMCLS" OR "THE COMPANY") - LETTER OF INTENT ENTERED BETWEEN THOMSON HOSPITALS SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF TMCLS AND ONCOCARE MEDICAL PTE LTD
The Board of Directors of TMCLS wishes to announce that Thomson Hospitals Sdn. Bhd. (“THSB”) a wholly-owned subsidiary of TMCLS had on 21 February 2024 entered into a Letter of Intent (“LOI”) with Oncocare Medical Pte Ltd (“OC Singapore”) to confirm THSB’s intention in exclusive negotiations towards a formal agreement between THSB and OC Singapore in regard to the provision of selected services to THSB in THSB’s operations of the Oncology Centre at Thomson Hospital Kota Damansara (“THKD”). (Both THSB and OC Singapore to be collectively referred to as the “Parties” and individually as a “Party”) Please refer to the attachment for the details of the announcement. This announcement is dated 22 February 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3423519

Attachments Attachment-LOI between THSB and OC Singapore-22.02.2024.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	TMC Life Sciences Berhad ("the Company") - Suspension of Group Chief Executive Officer
On behalf of the Company and further to the announcement made on 29 January 2024, the Board of Directors (“the Board”) wishes to announce that a second show cause letter dated 29 March 2024 (“Second Show Cause Letter”) was issued to Puan Wan Nadiah Binti Wan Mohd Abdullah Yaakob (“Puan Nadiah”) that contains allegations that are different from the first show cause letter that was issued on 29 January 2024 (“First Show Cause Letter”). The Audit and Risk Management Committee (“ARMC”) had carefully reviewed the written replies from Puan Nadiah to the First Show Cause Letter, whereby ARMC had found and concluded that the written replies were generally insufficient to answer the allegations stated in the First Show Cause Letter. The ARMC has reported its findings and conclusion to the Board. Depending on the findings and conclusion from the ARMC to Puan Nadiah’s response to the allegations stated in the Second Show Cause Letter, the Board will proceed with the next phase of the disciplinary process against Puan Nadiah for the allegations made in the First Show Cause Letter and, if applicable, the Second Show Cause Letter. The Board will make further announcements on this matter at the appropriate time. This announcement is dated 29 March 2024.